Adragos Pharma, a global pharmaceutical contract development and manufacturing organization (CDMO) headquartered in Munich, Germany, has acquired Baccinex, a Swiss-based expert in aseptic fill-finish manufacturing. This acquisition significantly enhances Adragos’ sterile manufacturing capabilities and marks a pivotal step in the expansion of its global network.

Baccinex, based in Courroux, Jura, Switzerland, brings over 20 years of experience in sterile fill-finish processes for both liquid and lyophilized vials. Operating from its EU-GMP and US FDA-certified facility, Baccinex specializes in clinical trial supplies and small-to-medium scale commercial production, offering world-class quality and reliability to its pharmaceutical clients.

Dr. Andreas Raabe, founder and CEO of Adragos Pharma, commented:

“The acquisition of Baccinex represents a significant milestone for Adragos. Baccinex’s proven expertise in sterile liquids and lyophilization, combined with its operational excellence, enhances our ability to provide integrated solutions from development through to commercial supply. This addition strengthens our position as a global partner of choice for high-quality pharmaceutical manufacturing.”

Expanding Adragos’ Manufacturing Capabilities in Jura, Switzerland

The acquisition of Baccinex strengthens Adragos Pharma’s presence in Switzerland, integrating a state-of-the-art manufacturing facility in Courroux, Jura. With a strong focus on both clinical and commercial sterile manufacturing, the Jura site significantly enhances Adragos’ ability to serve global pharmaceutical and biotech clients with high-quality, flexible, and scalable solutions.

Comprehensive Clinical & Commercial Manufacturing Services

The 6,200 m² facility specializes in aseptic fill-finish for liquid and lyophilized (bio)pharmaceutical products, supporting both early-phase development and full-scale commercial production under stringent EMA & FDA standards.

Clinical Manufacturing (Phase I, II, & III)

The Jura facility supports every phase of clinical manufacturing, guiding projects from feasibility studies and preclinical material preparation to GMP-compliant production. Its end-to-end approach ensures seamless transitions between development phases, delivering high-quality solutions tailored to clinical requirements. The facility is designed to handle small-batch clinical production and scale-up under strict EMA & FDA regulations, offering flexibility and reliability throughout the manufacturing process.

Commercial Manufacturing – Fill & Finish
The Jura facility specializes in two distinct dosage forms:

• Aseptic liquid filling – Sterile liquid products in glass vials
• Lyophilized products – Lyophilization with a 3.5 m² lyophilizer

With no minimum batch size requirements, the site is uniquely positioned to manufacture clinical batches from very small quantities of bulk solution (as little as 200-300ml), supporting pharmaceutical development from early-stage scale-up to full commercial production.

Broad Manufacturing Capabilities

The Jura facility provides expertise in handling a wide range of pharmaceutical products, including:
✅ Complex Formulations – peptides, monoclonal antibodies and other biological products
✅ Sterile Suspensions – Ophthalmic products, placebos, and diluents
✅ Regulatory & Quality Support – EMA & FDA standards compliance, stability studies, and process validation

With over 110 highly skilled professionals across 20+ disciplines, the Jura site ensures seamless technology transfer, robust project management, and high-precision manufacturing for clients worldwide.

A Strategic Step Towards Global Expansion

The integration of Baccinex into Adragos Pharma’s global network underscores the company’s commitment to providing high-quality, flexible, and scalable pharmaceutical manufacturing solutions. This acquisition not only strengthens Adragos' sterile manufacturing capabilities but also reinforces its position as a trusted partner in clinical and commercial pharmaceutical production.

By leveraging Swiss precision, regulatory excellence, and cutting-edge fill-finish technology, Adragos Pharma continues to expand its global footprint, supporting pharmaceutical innovators from development to market with seamless, end-to-end solutions.